logo
Train Advanced Practice Providers in Transnasal Endoscopy?

Train Advanced Practice Providers in Transnasal Endoscopy?

Medscape14-05-2025

Advanced practice providers (APPs) can be trained to perform transnasal endoscopy (TNE) with a single-use ultra-slim gastroscope with only topical anesthesia, a pilot study showed.
'Our study showed that TNE can be performed safely by APPs, is well tolerated by patients, and significantly impacted patient management,' Whitney Kucher, PA-C, with Northwestern Medicine, Chicago, told Medscape Medical News .
'The chief benefit of having APPs perform TNEs is increasing patient access and expediting management of upper GI [gastrointestinal] symptoms in patients,' said Kucher who presented the study at Digestive Disease Week (DDW) 2025.
The EvoEndo single-use endoscopy system received 510(k) clearance from the US Food and Drug Administration in early 2022.
The system includes a sterile, single-use, flexible gastroscope designed for unsedated transnasal upper endoscopy and a small portable video controller.
Unsedated TNE can be used to evaluate and diagnose a wide range of upper GI conditions that may require frequent monitoring, including eosinophilic esophagitis (EoE), dysphagia, celiac disease, gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), malabsorption, and abdominal pain.
Kucher and colleagues assessed the ability for APPs to use the EvoEndo system to perform safe and accurate esophageal assessment using in-office TNE, following training.
TNE training lasted about 4 weeks and consisted of a stepwise approach involving lectures, simulation-based training, and hands-on supervised TNEs (10 per APP).
Once training was completed, and after providing consent, 25 patients were enrolled to undergo supervised TNE by an APP. Their mean age was 55 years, and 58% were women.
Indications for TNE were uncontrolled GERD symptoms in 12 patients, history of EoE in six patients, high-risk screening for BE in five patients, and dysphagia in two patients.
Technical success was achieved in all but one patient (96%), and there were no adverse events.
All 25 patients completed the procedure, with 17 (72%) giving it a TNEase score of 1 (with ease/no discomfort) or 2 (mild/occasional discomfort). Only two patients reported a score of 4 (very uncomfortable) but still completed the exam.
The average TNE procedure time was 7.3 minutes.
TNE findings changed management in 23 of 25 (92%) patients. The test led to a change in proton pump inhibitor dosing or interval in 14 patients (56%). Esophagogastroduodenoscopy (EGD) interval was extended in five patients (20%) and scheduled sooner in three patients (12%). Two patients (8%) had no change in management.
The study team said more data are needed in terms of learning curves, competency metrics, and health economics before widespread adoption can be supported.
'We are working on developing a standardized training plan so we can train more GI APPs in our department. We have plans to start an APP-driven TNE program in the coming months,' Kucher told Medscape Medical News .
Caveats and Cautionary Notes
Commenting on this study for Medscape Medical News , Amitabh Chak, MD, president of the American Society for Gastrointestinal Endoscopy, noted that the results are 'similar to older studies where TNE appeared quite promising and APPs could be trained. There have been previous studies that APPs can perform colonoscopies and EGDs.'
Chak cautioned that previous studies showed that it took at least 50 supervised examinations for APPs to achieve the needed skills.
'Intubation transnasally can be painful for patients if not done with skill. Cognitive skills take longer. The gastroesophageal junction is dynamic, and recognition of subtle pathology takes training,' Chak noted.
'TNE has been around at least two decades. The challenge with uptake of TNE for Barrett's screening has been acceptance by primary care physicians, patients and payers,' Chak told Medscape Medical News .

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HistoSonics completes pivotal histotripsy system trial enrolment
HistoSonics completes pivotal histotripsy system trial enrolment

Yahoo

time21 minutes ago

  • Yahoo

HistoSonics completes pivotal histotripsy system trial enrolment

As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company's prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm. Patients will be treated with the Edison system and followed for five years post-procedure, with data at the 90-day evaluation point to be submitted in support of regulatory approval with the US Food and Drug Administration (FDA). The Edison system uses a technology called histotripsy, involving the delivery of non-thermal, non-invasive focused ultrasound waves to target and eliminate cancerous liver tissue. The system received de novo clearance from the US Food and Drug Administration (FDA) in 2023 and last month secured its first major insurance coverage from a new healthcare policy from Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network. HistoSonics' vision is for its Edison system to become a 'foundational, non-invasive' solution across a range of clinical applications, the company's CEO, Mike Blue stated. 'Completing enrolment in our pivotal kidney tumour trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumour types and indications,' said Blue. In May, Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet Clinical Need Authorisation (UCNA) under the UK's Innovative Devices Access Pathway (IDAP), launched by the UK Government in 2023 to help fast-track 'transformative medical technologies' into the healthcare system. As first reported by the Financial Times last month, HistoSonics is seeking a valuation of more than $2.5bn for a takeover of the company, with Medtronic, GE HealthCare and Johnson & Johnson (J&J), a longtime backer of HistoSonics, among the interested parties evaluating the business. J&J most recently participated in HistoSonics' $102m Series D funding round. "HistoSonics completes pivotal histotripsy system trial enrolment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BayCare and Northwestern Medicine partner to improve healthcare services in Florida
BayCare and Northwestern Medicine partner to improve healthcare services in Florida

Yahoo

time4 hours ago

  • Yahoo

BayCare and Northwestern Medicine partner to improve healthcare services in Florida

US-based health systems BayCare and Northwestern Medicine have partnered to broaden access to medical treatment and improve clinical research, training and education for physicians in West Central Florida. The initiative is expected to increase BayCare's capacity to attract, retain and train healthcare professionals to meet increasing patient demands in the region. It is part of BayCare's growth strategy for the Florida region, particularly the Tampa Bay area. BayCare president and CEO Stephanie Conners said: 'This isn't the beginning, it's the next step in a journey we've been focused on for years. 'West Central Florida deserves more access to academic medicine and by entering into a strategic collaboration with Northwestern Medicine, we will accelerate our trajectory as an academic health system.' Both organisations have signed a definitive agreement and have begun the first phase of the partnership, focusing on educational and professional development for clinicians and clinical research advancement. The partnership was announced on 5 June at Tampa Bay Park, where BayCare recently acquired three office buildings. Northwestern Memorial HealthCare president and CEO Howard Chrisman said: 'We are focused on collaborating with like-minded organisations that are driven by providing patients with greater access to world-class compassionate care, closer to where they live and work. 'By collaborating with BayCare, we have the opportunity to train and educate the next generation of medical professionals and transform the clinical offerings to patients in West Central Florida.' Northwestern Medicine provides care across 11 hospitals and more than 200 ambulatory and diagnostic sites in Chicago, Illinois, with Northwestern Memorial Hospital as its primary facility. BayCare operates 16 hospitals and numerous other facilities. The partnership with Northwestern Medicine will not affect its ownership, leadership or board composition. Last year, BayCare partnered with Cadence to launch a remote patient monitoring and responsive virtual care programme. "BayCare and Northwestern Medicine partner to improve healthcare services in Florida" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Avicenna.ai scoops CE marks for two AI fracture detection tools
Avicenna.ai scoops CE marks for two AI fracture detection tools

Yahoo

time6 hours ago

  • Yahoo

Avicenna.ai scoops CE marks for two AI fracture detection tools

French artificial intelligence (AI)-based medical imaging company has secured CE marks for a pair of radiologic screening tools to detect fractures from CT scans. CINA-VCF Quantix is an AI algorithm is used to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing CT scans for unrelated conditions, while CINA-CSpine is designed for the detection and triage of cervical spine fractures. Both tools gained 510(k) clearance from the US Food and Drug Administration (FDA) in 2024, while the tools' receipt of CE mark follows clearance on five other AI tools in 2024 under the EU's Medical Device Regulation (EU MDR). For use in patients aged 50 and above who are undergoing patients undergoing CT scans of the chest or abdomen for other conditions, CINA-VCF Quantix automatically labels vertebrae and calculates vertebral height loss ratios in the thoracic and lumbar spine. In cases where a vertebral height loss ratio exceeds 20%–25%, a figure indicative of a moderate- to severe VCF, the algorithm generates prompts notifying radiologists to report their early findings in support of proactive patient care, Avicenna stated. co-founder and CEO, Cyril Di Grandi commented: "Osteoporotic vertebral fractures can have a profound impact on patients' quality of life. "By encouraging the reporting of VCF presence and severity, CINA-VCF Quantix has the potential to make a real difference in long-term patient outcomes." CINA-CSpine is designed to automatically flag suspected acute cervical spine fractures through radiologists' existing systems. Di Grandi continued: "The launch of CINA-CSpine in the European market marks a significant step forward in trauma care. By reducing the time between scan and diagnosis, we're helping radiologists catch cervical spine fractures faster and more reliably.' A 2023 report on AI in healthcare by GlobalData forecasts that global revenue for AI platforms across the sector will reach a valuation of almost $19bn by 2027, with the radiology field seeing some of the highest implementation of AI technologies. Research indicates that thoracolumbar fusion procedures, one of the most common spine surgery types, are in growing demand, with thoracolumbar procedures such as anterior lumbar interbody fusion (ALIF) and posterior lumbar fusion (PLF) in the US projected to see respective rises from 46,903 to 55,528 and 248,416 to 297,994 between 2020 and 2040. According to GlobalData, the spinal fusion market segment, of which thoracolumbar fusion is a part, is growing at a CAGR of 2.3% and forecast to reach a valuation of around $11.23bn by 2033. " scoops CE marks for two AI fracture detection tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store